Clinically Important Ocular Reactions to Systemic Drug Therapy

Drug Safety

Volumn 9, Issue 3, 1993, Pages 196-211

  Rennie, Ian G ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARMUSTINE; CHLORAMPHENICOL; CHLOROQUINE; CHLORPROMAZINE; CISPLATIN; CORTICOSTEROID; CYCLOSPORIN; DEFEROXAMINE; DIGOXIN; DISULFIRAM; ETHAMBUTOL; FLUOROURACIL; GOLD; HYDROXYCHLOROQUINE; INDOMETACIN; IPRATROPIUM BROMIDE; METHOXSALEN; METOPROLOL; METRONIDAZOLE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; OXPRENOLOL; PENICILLAMINE; PERHEXILINE; PROPOFOL; QUININE; RETINOID DERIVATIVE; SULFONAMIDE; TAMOXIFEN; TETRACYCLINE; THIORIDAZINE; TUBERCULOSTATIC AGENT; VINCRISTINE;

AMBLYOPIA; CATARACT; CONJUNCTIVITIS; CORNEA DISEASE; CORNEA EROSION; EYE DISEASE; HUMAN; HYPOGLYCEMIA; INTRAOCULAR HEMORRHAGE; INTRAOCULAR HYPERTENSION; KERATOPATHY; LIVER DYSFUNCTION; MYASTHENIA GRAVIS; MYOPIA; NIGHT BLINDNESS; NYSTAGMUS; OPTIC NERVE DISEASE; ORAL DRUG ADMINISTRATION; PAPILLEDEMA; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; RETINA MACULOPATHY; RETINOPATHY; REVIEW; VISUAL HALLUCINATION; VISUAL IMPAIRMENT;

EYE DISEASES; HUMAN; PHARMACEUTICAL PREPARATIONS;

EID: 0027524493     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199309030-00005     Document Type: Review

References (123)

1. Ocular complications of vincristine therapy
2. Downbeat nystagmus due to anticonvulsant toxicity
3. Reversible ocular toxicity related to tamoxifen therapy
4. Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate
5. Optic disc edema after bone marrow transplantation
6. Presenile cataracts in phenytoin-treated epileptic patients
7. Quinine amblyopia
8. Ocular toxicity from ethambutol
9. Ocular assessment of patients treated with tamoxifen
10. Carbamazepine-induced oculgyric crisis
11. Posterior sub-capsular cataracts induced by corticosteroids in patients with rheumatoid arthritis
12. Blepharoconjunctivitis: a side effect of 13-cis-retinoic acid therapy for dermatological diseases
13. Massive spontaneous subretinal hemorrhage
14. Myasthenia gravis and penicillamine therapy of rheumatoid arthritis
15. The mechanism of transient myopia induced by sulphonamide therapy
16. Posterior subcapsular cataracts in steroid treated children
17. Long-term course of chloroquine retinopathy after cessation of medication
18. Epithelial depostition of gold in the cornea in patients receiving systemic therapy
19. Chlorpromazine-induced anterior segment changes
20. Conjunctival pigmentation associated with tetracycline medication
21. Visual toxicity of synthetic retinoids
22. Subconjunctival hemorrhage as a complication of ophthalmodynamometry in an anticoagulated patient
23. Indomethacin, reduced retinal sensitivity, and corneal deposits
24. Unusual ocular lesions in a case of systemic lupus erythematosus
25. Punctal-canalicular stenosis related to systemic fluorouracil therapy
26. Ocular manifestations of ethambutol
27. Ocular toxicity due to rifampicin
28. Ocular toxicity following ethambutol in standard dosage
29. Ocular side-effects of ibuprofen
30. Internuclear ophthalmoplegia caused by phenothiazine intoxication
31. Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis
32. Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study
33. Posterior subcapsular lens opacities in patients on long term corticosteroid therapy
34. Amiodarone keratopathy. Drug induced lipid storage disease
35. Myasthenia gravis and D-penicillamine
36. The use of Amsler Grids in early chloroquine retinopathy
37. Ocular effects and safety of antimalarial agents
38. Transient myopia due to tetracycline
39. Delayed-onset chloroquine retinopathy
40. Optic neuropathy and amiodarone therapy
41. Intraocular hemorrhage and blindness associated with systemic anticoagulation
42. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity
43. Amiodarone-induced lens opacities
44. Adverse ocular reactions possibly related with isoretinoin
45. Primidone, diphenylhydantoin and phenobarbital: aspects of acute and chronic toxicity
46. Abnormalities of the pupil and visual-evoked potential in quinine amblyopia
47. HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis
48. Amiodarone optic neuropathy
49. Severe ocular side effects of perhexilene maleate: case report
50. Ocular toxicity due to rifampicin
51. Papillopathy caused by amiodarone
52. Ocular flutter in vidarabine therapy
53. Systemic steroids and ocular fluid dynamics
54. Retinal edema secondary to oral contraceptives
55. Tear duct fibrosis (dacryostenosis) due to 5-fluorouracil
56. Optic neuritis and optic atrophy following chloramphenicol in cystic fibrosis patients
57. Unilateral fixed dilated pupil associated with nebulised ipratropium bromide
58. Transient myopia induced by sulfonamides
59. Papilloedema in patients taking perhexiline maleate
60. Ocular effects in long-term amiodarone therapy
61. Ocular changes from therapy with amiodarone
62. Tamoxifen retinopathy: a clinicopathologic report
63. Tamoxifen retinopathy
64. Amiodarone keratopathy. Correlation to dosage and duration
65. Corticosteroid-induced glaucoma
66. Congenital cataract and maternal steroid ingestion
67. Ocular manifestation of propofol allergy
68. Visual system toxicity following intra-arterial chemotherapy
69. Diphenylhydantoin metabolism, blood levels and toxicity
70. The ocular toxicity of ethambutol and its relation to dose
71. Ocular complications to drugs: visual changes
72. Localization of 8-methoxypsoralen in ocular tissues
73. Massive intraocular hemorrhage associated with anticoagulation and age related macular degeneration
74. Penicillamine-induced ocular myasthenia gravis in rheumatoid arthritis
75. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma
76. Amitriptyline and glaucoma
77. Ipratropium bromide induced angle closure glaucoma
78. Myopia during bromocriptine therapy
79. Optic nerve ultrastructure following amiodarone therapy
80. Chloroquine retinopathy: is there a safe daily dose?
81. Tamoxifen retinopathy
82. Progressive chorioretinopathy after receiving thioridazine
83. Pain upon eye movement following digoxin absorption
84. Pigmented conjunctival cysts following tetracycline/minocycline therapy
85. Carbamazepine-induced ophthalmoplegia
86. Bilateral optic neuropathy associated with amiodarone therapy
87. Disulfiram-induced optic neuritis
88. Cataracts in patients with rheumatic diseases treated with corticosteroids
89. Nebulised ipratropium bromide and salbutamol causing closed-angle glaucoma
90. Ocular toxicity of desferioamine — an example of copper promoted auto-oxidative damage?
91. Toxic amblyopia from ibuprofen
92. Ophthalmological safety of chloroquine
93. Bilateral optic neuritis evolved during tamoxifen treatment
94. Metronidazole and optic neuritis
95. Deposits in the lens and cornea of the eye during long-term chlorpromazine medication
96. Acute angle closure glaucoma occurring after nebulized bronchodilator treatment with ipratropium bromide and salbutamol
97. Ocular manifestations of digitalis toxicity
98. Use of contrast sensitivity measurement in the detection of subclinical ethambutol toxic neuropathy
99. Ocular toxicity associated with high-dose carmustine
100. Ocular toxic finding with prolonged and high dosage chlorpromazine intake
101. Effect of corticosteroids on cataract formation
102. Spontaneous hyphema during hemodialysis
103. Amitriptyline ophthalmoplegia
104. Visual loss associated with oral contraceptives
105. Phenytoin-induced ophthalmoplegia
106. Steroid cataracts: posterior subcapsular cataract formation in rheumatoid arthritis patients on long-term steroid therapy
107. Raised intracranial pressure due to perhexiline maleate
108. Central retinal vascular occlusion associated with oral contraceptives
109. Digoxin intoxication resulting in retrobulbar optic neuritis
110. Corticosteroid-induced toxic optic neuropathy
111. Corticosteroid treatment for inflammatory bowel disease in pedriatic patients increases intraocular pressure
112. Retinopathy caused by treatment with tamoxifen in low dosage
113. Ocular side effects of cancer chemotherapy
114. Adverse effects of chloroquine and antimalarial drugs on ocular structures
115. Oral contraceptives and neuro-ophthalmologic interest
116. Cyclosporine-induced trichomegaly
117. Lenticular chrysiasis in oral chrysotherapy
118. Abnormal retinal function associated with isotretinoin therapy for acne
119. Digoxin retinal toxicity: clinical and electrophysiologic evaluation of cone dysfunction syndrome
120. Cyclosporin A-induced reversible cortical blindness
121. Untoward effects associated with practolol administration: oculomucocutaneous syndrome